Research Article

MicroRNA-613 Enhances Nasopharyngeal Carcinoma Cell Radiosensitivity via the DNA Methyltransferase 3B/Tissue Inhibitor of Matrix Metalloproteinase-3/Signal Transducer and Activator of Transcription-1/Forkhead Box O-1 Axis

Liqiang Deng,1 Qing Yin,2 Shuyun Liu,3 and Debao Luo4

1Department of Pediatric Otolaryngology, The First People’s Hospital of Chenzhou, Hunan Province 423000, China
2Department of Pediatric Gastroenterology, The First People’s Hospital of Chenzhou, Hunan Province 423000, China
3Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Taiping Avenue 25, Luzhou 646000, China
4Department of Otorhinolaryngology, The First People’s Hospital of Chenzhou, Hunan Province 423000, China

Correspondence should be addressed to Liqiang Deng; klsq99xz50@163.com and Debao Luo; debaolu1208@163.com

Received 26 April 2022; Revised 5 July 2022; Accepted 13 July 2022; Published 26 August 2022

Academic Editor: Luca Falzone

Copyright © 2022 Liqiang Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Nasopharyngeal carcinoma (NPC), defined as a head and neck cancer malignancy arising from the epithelium of the nasopharynx, is associated with leukprognoses and increased lymphocyte infiltration [1, 2]. Interestingly, NPC has a dramatically skewed geographic distribution across the world, with significantly high incidence in East and Southeast Asia [3]. Epstein Barr virus represents the leading factor in the etiology of NPC; in addition, genetic factors and environmental and dietary causes can also precipitate NPC [4, 5]. Currently, radiotherapy is regarded as the gold-standard treatment for NPC [6]. However, the onset of radiation resistance poses a major hindrance in NPC treatment [7]. Accordingly, preventing radioresistance and increasing radiosensitivity are of the utmost importance for improving NPC patient prognosis and increasing 5-year survival rates [8]. In lieu of the same, it is imperative to expand on the

MicroRNA-613

MicroRNA (miRNA) expression patterns in NPC tissues were detected, and its correlation with clinical indexes was analyzed. NP-69 and C666-1 cell lines were selected for cellular experimentation. Radioresistant cell line C666-1R was obtained by fractionated radiation. Cell viability, survival fraction, and apoptosis were detected by CCK-8, colony formation assay, and flow cytometry. The binding relation between miR-613 and DNMT3B was verified by dual-luciferase and RIP assays. miR-613 targeted DNMT3B. miR-613 overexpression reduced C666-1R cell viability and survival fraction and increased apoptosis, while C666-1 cells with silencing miR-613 presented the opposite trends. miR-613 and DNMT3B overexpression led to enhanced C666-1R cell viability and survival fraction and decreased apoptosis. miR-613 reduced TIMP3 methylation and elevated TIMP3 protein level by inhibiting DNMT3B. miR-613 enhanced NPC radiosensitivity by inhibiting the DNMT3B/TIMP3/STAT1/FOXO1 pathway. Collectively, miR-613 inhibited DNMT3B, reduced TIMP3 methylation, and increased TIMP3 protein level, thus inhibiting the STAT1/FOXO1 pathway and enhancing the radiosensitivity of NPC cells.
potential mechanism of NPC radiosensitivity, provide novel effective strategies for clinical treatment, and prolong the survival time of patients with NPC.

microRNAs (miRNAs) are well-established as a group of small noncoding RNAs functioning in the posttranscriptional regulation of gene expression, also known for their crucial ability to regulate a variety of cellular activities, such as cell differentiation, growth, apoptosis, and development. Moreover, accumulating studies have indicated the association of miRNAs with various diseases, such that currently ongoing miRNA-mediated clinical trials have shown promising results in the treatment of viral infection and cancer [9]. As an important factor of posttranscriptional regulation, miRNAs are also capable of participating in ionizing radiation responses of cancer cells via the regulation of the cell cycle and apoptotic pathways [10–12]. What is more, hundreds of miRNAs have been discovered in diverse animals, and many of these are phylogenetically conserved [13]. miRNAs are 18–25 nucleotide long noncoding RNA molecules with the function of posttranscriptional gene regulation, which have attracted extensive attention as potential cancer regulators and biomarkers. Some miRNAs have tumor-suppressive or carcinogenic effects in oral carcinogenesis [14] and can be used as the biomarker for early oral cancer [15] and screening biomarkers for diagnosis and screening of colorectal carcinoma, sessile serrated lesions [16], and renal cell carcinoma patients [17]. Garnering our attention, miRNAs are associated with the malignant biological characteristics of cancer cells, including radiosensitivity [18, 19]. Furthermore, miRNA imbalances can contribute to tumor progression and metastasis. For instance, one such miRNA, namely, miR-613, confers an anticancer role in bladder cancer by targeting SphK1 [20]. In addition, miR-613 exhibits a tumor-suppressive role in several types of cancer [21]. One prior study uncovered that miR-613 plays an anticancer role in hepatocellular carcinoma by targeting tryptophan 5-monooxygenase activation protein [22]. Similarly, miR-613 was previously shown to inhibit proliferation, invasion, and tumor formation of retinoblastoma cells by targeting E2F transcription factor 5 [23]. Moreover, miR-613 can attenuate the Warburg effect in gastric cancer by targeting g6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 [24]. miR-613 targets sex-determining region Y-box 9 to play an antitumor role in glioma cells [25]. miR-613 inhibits the proliferation, migration, and invasion of thyroid papillary carcinoma cells by directly targeting transglin 2 [26]. On the other hand, knockdown of miR-613 promotes the proliferation and metastasis of pancreatic cancer cells by facilitating Notch3 expression and regulating the Notch3 pathway [27]. Long noncoding RNA cytoskeleton regulator RNA has also been previously indicated to facilitate cell metastasis and invasion by titrating miR-613 in NPC [28]. Similarly, the family with sequence similarity 225 member B promotes the proliferation and metastasis of NPC via the miR-613/ cyclin D2 axis [29]. Besides, miR-613 can further inactivate the AKT signal pathway by targeting fibronectin I, thus exerting antiangiogenic effects on NPC cells [30]. Together, these shreds of evidence highlight the potential involvement of miR-613 in the progression of NPC. However, whether miR-613 affects the radiosensitivity of NPC remains largely unknown.

The malignant transformation of normal cells is driven by genetic and epigenetic changes, and the dynamic regulation of DNA methylation serves as a key epigenetic mechanism for the occurrence, maintenance, and progression of cancer [31]. Moreover, epigenetic changes are primarily manifested as changes in miRNA levels and DNA methylation status [32]. DNA methyltransferase 3B (DNMT3B), as a major DNA methyltransferase, is known to function in de novo methylation of DNA, which exerts critical roles in various important biological functions, while also being involved in tumorigenesis, progression, and metastasis through DNA methylation [33–36]. What is noteworthy is that silencing DNMT3B restores and activates p53 and p21 through DNA demethylation, ensuing cell cycle arrest and apoptosis, thus improving the radiosensitivity of NPC [37]. Tissue inhibitor of matrix metalloproteinases-3 (TIMP3) is a special member of the TIMP family, which possesses the ability to regulate tumor growth, metastasis, angiogenesis, and other physiological progress through matrix metalloproteinases [38]. Furthermore, as an independent and promising biomarker, TIMP3 plays a regulatory role in a plethora of cancers [39–41] and is lowly expressed in NPC tissues [42]. In addition, TIMP3 methylation has been documented in several malignancies [34, 43, 44]. Strikingly, inhibition of DNMT3B reduces TIMP3 methylation levels and enhances TIMP3 protein levels, thus modulating the STAT1/FOXO1 pathway in breast cancer [34]. However, no studies have explored whether miR-613 regulates the DNMT3B/TIMP3/STAT1/FOXO1 pathway in the radiosensitivity of NPC cells. Accordingly, the current study sets out to investigate the potential molecular mechanism of miR-613 in NPC cell radiosensitivity by targeting DNMT3B, affecting TIMP3 methylation level, and activating the STAT1/FOXO1 pathway.

2. Materials and Methods

2.1. Ethics Statement. The current study was approved by the ethics committee of the First People’s Hospital of Chenzhou and performed in strict accordance with the code of ethics. Signed informed consents were obtained from all participants after a comprehensive understanding prior to specimen collection.

2.2. Sample Collection. A total of 121 pairs of adjacent normal tissues and tumor tissues from NPC patients (including 81 males and 40 females; aged 40–68 years with a mean calculated age of 51.3 ± 7.2 years) were collected at the First People’s Hospital of Chenzhou from September 2016 to September 2020. The inclusion criteria [45] were as follows: (1) patients with NPC confirmed by biopsy and pathology; (2) patients who did not receive treatment prior to inclusion; (3) patients without distant metastasis; (4) patients receiving intensity-modulated radiotherapy; and (5) patient with complete clinical data. Patients not meeting any one of the above inclusion criteria were excluded and were not included for sample collection. In addition, none of the included patients received radiotherapy or chemotherapy before operation.
According to the tumor, node, and metastasis (TNM) staging [46], there were 21 cases at stage I, 20 cases at stage II, and 80 cases at stages III and IV.

2.3. Cell Culture and Grouping. NP-69 and C666-1R cells were procured from ATCC (Manassas, VA, USA). C666-1R cells were prepared by in vitro fractionation radiation [47, 48]). All cell lines were cultured in RPMI-1640 medium (22400089, Gibco Company, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and plated into 6-well plates (at a density of $1 \times 10^5$ cells/well), and subcultured in a humidified incubator with saturated humidity and 5% CO$_2$ at 37°C.

Upon achieving 70-80% confluence, the C666-1R or C666-1 cells were plated into 6-well plates (at a density of $1 \times 10^5$ cells/well), cultured in a humidified incubator with saturated humidity and 5% CO$_2$ at 37°C, and allocated and treated as according as follows: the NP-69 group, the C666-1 group, the C666-1R group, the C666-1R + miR mimics group (C666-1R transfected with 1 miR-613 mimics), the C666-1R + miR mimics + oe-DNMT3B group (C666-1R co-transfected with miR-613 mimics and oe-DNMT3B plasmid), the C666-1R + oe-DNMT3B group (C666-1R co-transfected with miR-613 mimics and oe-DNMT3B plasmid), and the C666-1R + oe-DNMT3B + si-STAT1 group (C666-1R co-transfected with miR-613 mimics, oe-DNMT3B and si-STAT1 plasmid), and the C666-1R + oe-DNMT3B + si-STAT1 group (C666-1R co-transfected with miR-613 mimics, oe-DNMT3B, si-STAT1, and oe-DNMT3B plasmid). Further experimentation was carried out after 12 h mimics NC, miR-613 mimics, oe-STAT1, oe-DNMT3B, and oe-DNMT3B + si-STAT1 transfected into cells using the Lipofectamine 2000 reagent (Invitrogen, Burlington, ON, Canada). The final transfection concentration was 100 nM. All the above-utilized plasmids were purchased from the Life Technologies Corporation.

2.4. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The total RNA content was extracted from 100 mg frozen tissues or cells using the TRIzol reagent (12183555, Thermo Fisher Scientific Inc., NY, USA) in a one-step manner. CDNA was synthesized by means of reverse transcription according to the instructions of PrimeScript RT-PCR kits (Takara, Tokyo, Japan). RT-qPCR was performed with SYBR FAST qRT-PCR Master Mix kits (Invitrogen). PCR reaction conditions were as follows: pre-denaturation for 15 min at 95°C, and 40 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 55°C, and extension for 30 s at 72°C. U6 was adopted as the internal control for miR-613, and GAPDH was utilized as the internal control for DNM3T3B, respectively. Following amplification, the solution curve was analyzed, and gene expression in each group was calculated using the $2^{-\Delta\Delta Ct}$ method. Primer sequences are shown in Table 1.

### Table 1: PCR primer sequences.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequences (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-613</td>
<td>F 5′-AGGAAATGTCCCTCTTTCGCT-3′</td>
</tr>
<tr>
<td></td>
<td>R 5′-CTGTGGGTCCTGCGTTGAGT-3′</td>
</tr>
<tr>
<td>DNMT3B</td>
<td>F 5′-GTCAGGCCGCTGATGAGTGA-3′</td>
</tr>
<tr>
<td></td>
<td>R 5′-TCATGACTGGCAGAACAGA-3′</td>
</tr>
<tr>
<td>GAPDH</td>
<td>F 5′-CTGGAAGGTCGGGTACCCAG-3′</td>
</tr>
<tr>
<td></td>
<td>R 5′-CCTGGAGATGTTGTGAGGATT-3′</td>
</tr>
<tr>
<td>U6</td>
<td>F 5′-AACGTTCAAGAATTTGCCGTA-3′</td>
</tr>
</tbody>
</table>

2.5. Western Blot Analysis. C666-1 and C666-1R cell homogenates were added with protein lystate (R0278, Sigma-Aldrich, St. Louis, MO, USA) and centrifuged at a rate of 12000 r/min for 20 min at 4°C. Next, the supernatant was subpacked, and total protein concentration in homogenates was detected. Subsequently, 10% sodium dodecyl sulfate separating gel and stacking gel were prepared. Following mixing with the loading buffer, the protein samples were boiled for 5 min at 100°C. Afterwards, the proteins were placed in an ice bath, centrifuged, and equally added to each lane using a micropipette for electrophoresis. Thereafter, the proteins on the gel were transferred onto nitrocellulose membranes, which were blocked with 5% skim milk overnight at 4°C and probed with anti-DNMT3B (ab9822, dilution ratio of 1:1000, Abcam Inc., Cambridge, MA, USA), anti-FOXO1 (ab52857, dilution ratio of 1:1000, Abcam), and anti-GAPDH (ab9485, dilution ratio of 1:1000, Abcam) at room temperature for 1 h. The membranes were rinsed 3 times with phosphate-buffered saline (PBS) at room temperature, 5 min each. After that, the secondary antibody goat antirabbit IgG H&L (HRP) (ab6721, dilution ratio of 1:2000, Abcam) was added for 1-h incubation at room temperature, followed by 3 PBS rinses at room temperature, 5 min each. Afterwards, the membranes were immersed in enhanced chemiluminescence solution (Pierce, Waltham, MA, USA) for 1 min at room temperature. The liquid was absorbed, and the membranes were covered with plastic film and exposed to X-ray film for observation. The gray value ratio of the target band to the internal reference band was regarded as the relative protein expression, with GAPDH serving as the internal reference.

2.6. Cell Counting Kit-8 (CCK-8) Assay. Cells (at a density of $5 \times 10^3$ cells/mL) were cultured in 96-well plates, with 6 duplicate wells set for each group, and each well was added with 100 μl cell culture medium. After 24 h, cells in the plates well adhered to the wall and then were irradiated with 6-MV X-ray using an accelerator (Elekta Instruments AB, Stockholm, Sweden) at a source-skin distance of 100 cm and a dose rate of 500 cGy/min. The irradiation doses of cells were set to 0, 2, 4, and 8 Gy, respectively. After irradiation, the cells were cultured in an incubator (51020241, Thermo...
Fish) for 48 h. Afterwards, 100 μL medium and 10 μL CCK-8 reagent (C0037, Beyotime, Shanghai, China) were successively added to each well under the provided instructions with the CCK-8 kits. After 1–2-h incubation at 37°C, optical density (OD) values at 450 nm were detected using a microplate reader (Multiskan FC, Thermo Fisher). Three parallel wells were set for each group, with the mean value recorded. The cell proliferation curve was plotted with time as the abscissa and OD value as the ordinate.

2.7. Colony Formation Assay. Cells were cultured overnight on 6-well plates at a density of 1 × 10^4 and then treated with 4 Gy irradiation. After 10 days, the cells were fixed with 4% paraformaldehyde, stained with Giemsa stain kit (DM0002, LEAGE, Beijing Leagene Biotechnology, Beijing, China), and then counted under a microscope (CX23, Olympus, Tokyo, Japan).

2.8. Flow Cytometry. Cells were rinsed three times with PBS and suspended in the buffer and then subjected to staining with propidium iodide containing 50 μg/mL RNaseA (Sigma-Aldrich) and fluorescein isothiocyanate-AnnexinV (APOAF, Sigma-Aldrich). A FACScan flow cytometer (Beckman Coulter, Fullerton, CA, USA) was utilized for flow cytometric analysis. Data were analyzed using the FlowJo software (Tree Star, San Carlos, CA, USA).

2.9. Dual-Luciferase Reporter Gene Assay. The binding sites between miR-613 and DNMT3B were predicted and analyzed with the help of the StarBase database (http://starbase.sysu.edu.cn/index.php). Wild-type or mutant plasmids of DNMT3B (wt-DNMT3B/mut-DNMT3B) were constructed using pmirGLO vectors (GenePharma, Shanghai, China) and subsequently co-transfected with miR-613 mimic or miR-NC into C666-1 cells in strict accordance with the instructions of the Lipofectamine 2000 reagent (11668, Invitrogen). Luciferase activity was detected 48 h after transfection with the help of a dual-luciferase detection system (Promega, Madison, WI, USA).

2.10. Quantitative Real-Time Methylation-Specific PCR (qMSP). DNA content was extracted from cells under provided instructions of the QIAamp DNA Mini Kit (51304, Qiagen, Hilden, Germany). Bisulfite modification was subsequently carried out in strict accordance with the manufacturer’s instructions (Qiagen). DNA sequences were methylated (M) or unmethylated (U) with bisulfite-modified TIMP3, and the methylation level of TIMP3 in cells was detected by qMSP. TIMP3 methylated or unmethylated primer sequences are illustrated in Table 2 [34].

2.11. Statistical Analysis. Data were processed and mapped using the GraphPad Prism 8.0.1 software (GraphPad Software Inc., San Diego, CA, USA). A minimum of three independent cell experiments were carried out per group. Measurement data were presented as mean ± standard deviation (SD). The t-test or repeated variance analysis of variance (ANOVA) was adopted for comparisons between two groups, and one-way analysis of variance (ANOVA) was adopted for comparisons between multiple groups, along with Tukey’s multiple com-

Table 2: TIMP3 methylated (M) or unmethylated (U) primer sequences.

<table>
<thead>
<tr>
<th>Primer type</th>
<th>Primer sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>Forward: 5′-TCGAGAGATAGAAA TATTTTACGA-3′&lt;br&gt;Reverse: 5′-TAACATTAAAAAACACA AAAAAACGA-3′</td>
</tr>
<tr>
<td>U</td>
<td>Forward: 5′-TTGAGAGATAGAAA TATTTTATGA-3′&lt;br&gt;Reverse: 5′-TAACATTAAAAAACACA AAAAAACAA-3′</td>
</tr>
</tbody>
</table>

parisons test. A value of p < 0.05 was regarded as statistically significant.

3. Results

3.1. miR-613 Was Poorly Expressed in NPC Tissues and Cells and Associated with NPC Radiosensitivity. Collection and subsequent RT-qPCR analyses illustrated that the clinical samples of 121 cases of NPC patients presented decreased expression levels of miR-613 relative to adjacent normal tissues (p < 0.01) (Figure 1(a)). To further elucidate the correlation between the expression of miR-613 and NPC patient clinicopathological characteristics and prognosis, the 121 NPC patients were assigned into the high expression group and low expression groups according to the median value of miR-613 expression in tumor tissues. There were no significant correlations between the expression of miR-613 and gender, age, smoking history, and clinical stages, whereas there were significant correlations between miR-613 expression and N classification, T classification, and distant metastasis (all p < 0.01) (Table 3), which underscored the involvement of miR-613 in the progression of NPC.

Accumulating studies have further suggested the usage of miR-613 as an indicator of the radiosensitivity of cancer cells [49]. To investigate whether miR-613 could exert a similar role in the radiosensitivity of NPC, NPC cell line C666-1 was selected for in vitro experimentation, and the radioresistant NPC cell line C666-1R was obtained by in vitro fractionated radiation. CCK-8 was further carried out to detect the cell viability changes in C666-1 and C666-1R cells treated with radiation at the dose of 0, 2, 4, and 8 Gy. With the increase in radiation doses, the cell viability was significantly decreased in both C666-1 < C666-1R cells, and the change was the largest following 4 Gy irradiation (p < 0.01) (Figure 1(b)). In addition, C666-1R cells exhibited a higher survival fraction than C666-1 cells under 4 Gy radiation (p < 0.01) (Figure 1(c)). Furthermore, miR-613 level patterns in cells were detected using RT-qPCR, which revealed that compared with NP-69 cells, miR-613 was down-regulated in C666-1 and C666-1R cells; and the expression in tolerant C666-1R cells was relatively lower than that of the C666-1 cells (p < 0.01) (Figure 1(d)). Together, these findings highlighted that miR-613 might be involved in the regulation of NPC cell radiosensitivity.
3.2. Overexpression of miR-613 Improved NPC Cell Radiosensitivity. To further elaborate on the role of miR-613 in NPC cell radiosensitivity, we transfected C666-1R cells with miR-613 mimics to overexpress miR-613 expression and transfected C666-1 cells with miR-613 inhibitor to down-regulate miR-613 expression \((p < 0.01)\) (Figure 2(a)). Subsequent experimentation demonstrated that C666-1R cell viability was decreased under 0, 2, 4, and 8 Gy radiation after miR-613 overexpression, the surviving fraction was decreased, and the apoptosis rate was increased under 4 Gy radiation \((all \ p < 0.01)\); meanwhile, C666-1 cell viability was increased under 0, 2, 4, and 8 Gy radiation after miR-613 down-regulation, and the surviving fraction was increased, and the apoptosis rate was decreased under 4 Gy radiation (Figures 2(b)–2(d)). Overall, these findings indicated that overexpression of miR-613 exerted an enhancing effect on NPC cell radiosensitivity.

miR-613 increased NPC radiosensitivity by targeting DNMT3B. DNMT3B was associated with NPC radiosensitivity [37]. Further detection illustrated that DNMT3B was highly expressed in NPC tissues (Figure 3(a), \(p < 0.01\), and negatively correlated with miR-613 expression (Figure 3(b)). Subsequently, the targeted binding sites between miR-613 and DNMT3B were predicted using the StarBase database and verified with a dual-luciferase assay (Figure 3(c)). Moreover, the results of Western blot elicited higher protein levels of DNMT3B in C666-1R cell line relative to those in NP-69 and C666-1 cells \((p < 0.01)\) (Figure 3(d)). After miR-613 overexpression, the protein levels of DNMT3B in C666-1R cells were diminished; whereas after miR-613 knockdown, the protein levels of DNMT3B in C666-1 cells were enhanced (Figure 3(e), \(p < 0.01\)). These findings suggested that miR-613 was capable of targeting DNMT3B. Subsequently,
C666-1R cells were co-transfected with miR-613 mimics and oe-DNMT3B, followed by analyses of cell radiosensitivity. Subsequent results demonstrated augmented protein levels of DNMT3B in C666-1R cells (Figure 3(e), p < 0.05). Under 0, 2, 4, and 8 Gy radiation, cell viability was increased, cell surviving fraction under 4 Gy radiation was increased, and apoptosis was reduced (all p < 0.05) (Figures 3(f)–3(h)). Altogether, these findings indicated that miR-613 enhanced NPC radiosensitivity via inhibition of DNMT3B.

3.3. miR-613 Reduced TIMP3 Methylation by Inhibiting DNMT3B. TIMP3 was previously established to be lowly expressed in NPC tissues [42], and TIMP3 methylation is a common occurrence in many cancers [34, 43, 44]. DNMT3B further represents a major DNA methyltransferase regulated by miR-613. To explore whether miR-613 reduced the methylation level of TIMP3 in NPC cells by inhibiting DNMT3B expression, TIMP3 methylation level and its protein level patterns were detected in cells by qMSP and Western blot. Subsequent results illustrated that compared with NP-69 cells, the protein levels of TIMP3 in C666-1 and C666-1R cells were markedly elevated in C666-1R cells after transfection with miR-613 mimics, oe-DNMT3B, and si-STAT1. It was found that STAT1 levels were noticeably reduced, and FOXO1 levels increased, with C666-1R presenting with higher STAT1 levels than those in C666-1, and the protein levels of FOXO1 were decreased, with C666-1R presenting with lower STAT1 levels than those in C666-1 (Figure 5(a), p < 0.01). Moreover, C666-1R cells were co-transfected with miR-613 mimic, oe-DNMT3B, and si-STAT1. It was found that STAT1 levels were noticeably reduced, and FOXO1 levels were markedly elevated in C666-1R cells after miR-613 overexpression, while these trends were reversed in CNE-2R cells after miR-613 overexpression and DNMT3B overexpression. Lastly, STAT1 protein levels were significantly decreased, and FOXO1 protein levels were enhanced in C666-1R cells after transfection with miR-613 mimics, oe-DNMT3B, and si-STAT1, whereas C666-1R presented with decreased cell viability, reduced cell surviving fraction under 4 Gy radiation, and increased cell apoptosis under 2, 4, and 8 Gy radiation (Figures 5(a)–5(d), p < 0.05). Altogether, these findings highlighted that miR-613 increased the radiosensitivity of NPC cells by inhibiting the DNMT3B/TIMP3/STAT1/FOXO1 pathway.

4. Discussion

NPC represents a common head and neck malignancy arising from the epithelium of the nasopharynx, associated with
low survival rates in certain endemic areas [1]. Meanwhile, the last decade has witnessed the emergence of miRNAs as key regulators in diverse biological functions and disease progression [53]. Herein, the current study set out to elucidate the potential roles of miR-613 in NPC cell radiosensitivity, and our findings highlighted that miR-613 inhibited DNMT3B, reduced TIMP3 methylation, and increased TIMP3 protein level, thereby inhibiting the downstream STAT1/FOXO1 pathway and augmenting the radiosensitivity of NPC cells.

Our study is not the first of its kind to suggest the involvement of miRNA regulation of radiosensitivity in NPC cells [54]. Initial findings in our study demonstrated that miR-613 was poorly expressed in NPC tissues, and the aberrant expression of miR-613 was associated with N classification, T classification, and distant metastasis. Additional experimentation with increasing radiation doses revealed that there was a significant decrease in the cell viability of parental NPC cell line C666-1 and the radioresistant cell line C666-1R, and the change was the largest under 4 Gy...
**Figure 3: Continued.**

(a) Normal samples vs. tumor samples for relative DNMT3B mRNA level.

(b) Scatter plot showing the relative miR-613 level with a correlation coefficient of $r = -0.7888$ and $P < 0.0001$.

(c) Relative luciferase activity for wt-DNMT3B and mut-DNMT3B with DNMT3B and hsa-miR-613 sequences.

(d) Relative protein level of DNMT3B for NP-69, C666-1, and C666-1R cells.
irradiation, and C666-1 < C666-1R; meanwhile, C666-1R exhibited a higher survival fraction than C666-1 under 4 Gy radiation. Compared with NP-69 cells, miR-613 expression levels were down-regulated in C666-1 and C666-1R cells, while relative to the C666-1 cells, miR-613 expression levels were also diminished in the radiotolerant C666-1R cells. In accordance with our data, previous studies have documented that miR-613 expression is lowered in NPC cell lines and tissues [29]. Similarly, miR-613 was previously reported to exert effects on the cell radiosensitivity of cancers, such as nonsmall cell lung cancer, while also being implicated in cisplatin resistance of glioma [49, 55]. Altogether, these findings and evidence conclusively highlight the involvement of miR-613 in NPC cell radiosensitivity regulation.

Accumulating reports have further indicated the use of miR-613 as an indicator of the radiosensitivity of cancer cells [49]. To further elaborate on the role of miR-613 in NPC cell radiosensitivity, we overexpressed miR-613 expression in C666-1R cells and knocked down miR-613 expression in C666-1 cells. Subsequent experimentation demonstrated that following overexpression of miR-613, C666-1R cell viability was reduced under 0, 2, 4, and 8 Gy radiation, and the surviving fraction was repressed, and apoptosis rate was elevated under 4 Gy radiation, whereas C666-1 cells with silenced miR-613 presented with the opposite trends.
Consistently, a prior report suggested that hepatoma cells with overexpressed miR-613 were more sensitive to sorafenib or cisplatin treatment [56]. Together, our findings in conjunction with existing evidence highlight that overexpression of miR-613 augments NPC cell radiosensitivity.

Another key component of our study, the DNMT3B gene is known to play roles in tumorigenesis, metastasis, progression, and NPC cell radiosensitivity [33, 35–37]. Further detection revealed that DNMT3B was highly expressed in NPC tissues and negatively correlated with miR-613. We further validated the targeting relationship between miR-613 and DNMT3B using a dual-luciferase assay and came across higher DNMT3B protein levels in C666-1R cell line relative to NP-69 and C666-1 cells. In addition, overexpression of miR-613 led to diminished DNMT3B protein levels in C666-1R cells, while knockdown of miR-613 brought about an increase in DNMT3B protein levels in C666-1 cells, which underscores that miR-613 targeted DNMT3B. In accordance with our data, elevated DNMT3B expression in NPC tissues has been reported before [37]. Furthermore, we verified the role of the miR-613/DNMT3B axis in NPC cell radiosensitivity that after co-transfection with miR-613 mimics and oe-DNMT3B, there was an increase in DNMT3B protein levels in C666-1R cells. Meanwhile, under 0, 2, 4, and 8 Gy radiation, cell viability was augmented, survival fraction was stimulated, and apoptosis was reduced under 4 Gy radiation. Consistently, DNMT3B induced by radiation was previously indicated to promote NPC radioresistance through methylation of p21 and p53 [37]. Likewise, another study indicated that overexpression of DNMT3B contributes to radiotherapy failure, such that its inhibition represents a promising radiosensitizing strategy for patients with metastatic or
Figure 5: miR-613 enhanced NPC radiosensitivity by inhibiting the DNMT3B/TIMP3/STAT1/FOXO1 pathway. (a) Protein levels of STAT1 and FOXO1 in cells were detected by Western blot. (b) Cell viability changes of cells were detected using the CCK-8 method. (c) Cell survival fraction of cells was detected by cell colony formation assay. (d) Cell apoptosis was detected by flow cytometry. Three independent repeated tests were performed. Data were expressed as mean ± SD and analyzed using one-way ANOVA and Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01.
recurrent rhabdomyosarcoma tumors [57]. Exosomal miR-613 also exerts an inhibitory effect on lung cancer growth, while promoting the sensitivity to cisplatin [58]. Silencing has-circ000199 enhanced breast cancer chemosensitivity by promoting miR-613 expression [59]. Overall, these findings and data indicate that miR-613 enhances NPC radiosensitivity by targeting DNMT3B.

Furthermore, various novel studies have come across TIMP3 methylation in a myriad of cancers [34, 43, 44]. Herein, our results illustrated that TIMP3 methylation levels were augmented and TIMP3 protein levels were suppressed in C666-1 and C666-1R cells, with C666-1R cells showing the more obvious alteration; meanwhile, after miR-613 overexpression, TIMP3 methylation levels were suppressed, and TIMP3 protein levels were facilitated in C666-1R cells, whereas further DNMT3B overexpression reversed the above trends in C666-1R cells. Consistent lowly expressed TIMP3 was previously reported in NPC tissues [42], while knockdown of TIMP3 methylation was associated with alleviation of breast cancer [34]. In short, these findings and data make it plausible to suggest that miR-613 reduces TIMP3 methylation levels by inhibiting DNMT3B.

The last focus of our study, STAT1, is widely established to regulate cell radiosensitivity in various cancers [50–52]. To investigate whether miR-613 regulated NPC radiotherapy by inhibiting DNMT3B/TIMP3 and the STAT1/FOXO1 pathway, we detected STAT1 and FOXO1 protein levels in NP-69, C666-1, and C666-1R cells, and discovered that STAT1 protein levels were promoted and FOXO1 protein levels were decreased in C666-1 and C666-1R cells, with C666-1R cells showing the more obvious alteration. Moreover, STAT1 levels were markedly diminished, and FOXO1 levels were augmented in C666-1R cells after miR-613 overexpression, which were reversed after further DNMT3B overexpression, and restored by further silencing STAT1, in addition to decreased cell viability and surviving fraction and enhanced cell apoptosis in C666-1R cells. Consistently, STAT1 silencing has previously been shown to sensitize NPC cell line CNE-2R radioresistant to radiotherapy [60]. Moreover, human glioma cell radiosensitivity can similarly be enhanced by LITAF via the FOXO1 pathway [61]. Unsurprisingly, there is prior evidence to suggest that DNMT3B affects the progression of breast cancer by targeting the STAT1/FOXO1 pathway [62]. Altogether, these findings illustrated that miR-613 diminishes the radiosensitivity of NPC cells by inhibiting the DNMT3B/TIMP3 via activation of the STAT1/FOXO1 pathway for the first time.

In summary, the current study highlighted that miR-613 inhibited DNMT3B, reduced TIMP3 methylation, and increased TIMP3 protein level, thus inhibiting the downstream STAT1/FOXO1 pathway and enhancing the radiosensitivity of NPC cells. However, we only carried out the relevant mechanism research in NPC cell line, and our findings warrant in vivo validation experiments in future studies.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

All authors declare that there is no conflict of interests in this study.

**Authors’ Contributions**

Liqiang Deng and Qing Yin contributed equally to this work. All authors have contributed significantly, and all authors agree with the content of the manuscript.

**References**


FAM225B facilitates proliferation and metastasis of nasopharyngeal carcinoma by titrating miR-613 to regulate ANXA2 in nasopharyngeal carcinoma cells by regulating miR-613/CCND2 axis.

Disease Markers


